venerdì, 26 novembre 2021
6 Giugno 2019

FDA Grants Momelotinib Fast Track Designation in Myelofibrosis

June 5, 2019 – The FDA has granted momelotinib a fast track designation for use as a treatment of patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor. Sierra Oncology, the developer of the JAK1/JAK2/ACVR1 inhibitor, announced that it will launch the phase III MOMENTUM trial, which will evaluate momelotinib compared with danazol in symptomatic, anemic patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or … (leggi tutto)